barzolvolimab
·Code: CDX-0159
barzolvolimab: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Celldex Therapeutics, Inc. (CLDX) | Phase 2 |
Clinical Trials (1)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)
Frequently asked questions
Who is developing barzolvolimab?
barzolvolimab is being developed by Celldex Therapeutics, Inc..
How many clinical trials involve barzolvolimab?
BioSniper tracks 1 clinical trial involving barzolvolimab.
Get deeper analysis on barzolvolimab
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis